Selective inhibitor of phosphodiesterase type 4 (IC50
values are 1.9, > 100, > 100, > 100 and > 100 μ
M for human lung PDE4, lung PDE1, lung PDE2, heart PDE3 and platelet PDE-V respectively) that displays no significant PDE4 isozyme selectivity. Inhibits hydrolysis of cAMP in isolated human peripheral blood monocytes, eosinophils and T cells.� Displays anti-inflammatory and bronchodilatory effects in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4.
Turner et al.
In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan et al.
The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice: effect of adrenalectomy.
Cheng et al.